AstraZeneca has requested urgent approval from the U.S. Food and Drug Administration for long-acting antibody combination therapies to prevent Kovid-19.
AstraZeneca said in a statement on Tuesday that the UK drug manufacturer’s experiments had reduced the risk of contracting Kovid-19 by 77 percent after using the treatmentIf authorized, it will be the first therapy to prevent the coronavirus from spreading.
Maine Pangallos, executive vice president, said: “People at risk, such as those with a low level of immunosuppression, will not be able to get a protective response after being vaccinated, and the risk of contracting Kovid-19 remains high.”
“With this first global regulatory filing, we are one step closer to providing an additional alternative to vaccinating against Kovid-19,” he said.
Global Version Samsung Galaxy M51 M515F-DSN Mobile Phone 128GB ROM 8GB RAM 6.7″ 7000mAh NFC Snapdragon 730G Smartphone